SCN4B

SCN4B encodes Navβ4, a regulatory subunit of the cardiac sodium channel that also functions as a tumor-suppressive modulator of cell motility and a determinant of striatal neuron excitability (PMID:17592081, PMID:27917859). Navβ4 co-assembles with the SCN5A-encoded Nav1.5 α-subunit, and arrhythmia-associated mutations (e.g. L179F) increase late sodium current by altering channel gating, while other variants (p.Gly8Ser, p.Ala145Ser) reduce Navβ4 protein levels, both representing channel-dysregulating loss/gain-of-function mechanisms (PMID:17592081, PMID:31020414). Independently of ion channel activity, the intracellular C-terminus of Navβ4 suppresses RhoA activity to restrain cell migration and invasion, and Navβ4 inhibits epithelial-mesenchymal transition, shifting cells toward an epithelial state (increased E-cadherin, decreased N-cadherin, Vimentin, and Snail) (PMID:27917859, PMID:41685607). Consistent with a tumor-suppressive role, SCN4B is silenced by oncogenic microRNAs—miR-424-5p in colorectal cancer and miR-3175 in prostate cancer—each binding the SCN4B transcript to promote proliferation and metastasis (PMID:31785995, PMID:32833340). In the nervous system, Scn4b maintains the electrophysiological properties of striatal spiny projection neurons and modulates Huntington's disease motor, cognitive, and transcriptional phenotypes in vivo (PMID:41959367).

1. 2007 High

   Established that Navβ4 is a functional regulatory subunit of the cardiac sodium channel, answering whether SCN4B variants can directly alter channel gating and cause arrhythmia.

   Evidence Site-directed mutagenesis of L179F-β4 with heterologous co-expression with SCN5A in HEK293 cells and late sodium current recording

   PMID:17592081

   Open questions at the time

   • Structural basis of β4 binding to Nav1.5 not resolved
   • Effect of wild-type β4 on native cardiomyocyte channels not tested in vivo
2. 2016 High

   Revealed a non-channel function of Navβ4 by showing its intracellular C-terminus suppresses RhoA to restrain migration and invasion, decoupling its motility role from ion conduction.

   Evidence siRNA knockdown, overexpression and C-terminus domain rescue in breast cancer cells with RhoA activity assays, invasion/migration assays, xenograft metastasis models, and NaV channel blockade controls

   PMID:27917859

   Open questions at the time

   • Direct molecular link between the β4 C-terminus and RhoA regulators not defined
   • Whether C-terminus acts as adaptor or via an intermediate protein unknown
3. 2019 Medium

   Connected specific arrhythmia-associated SCN4B variants to reduced Navβ4 protein abundance, supporting a loss-of-function disease mechanism.

   Evidence Western blotting of p.Gly8Ser and p.Ala145Ser variant proteins expressed in cells

   PMID:31020414

   Open questions at the time

   • Single method (Western blot) without electrophysiology or co-expression functional assay
   • Mechanism of reduced expression (stability vs translation) not determined
4. 2019 Medium

   Identified SCN4B as a direct target of an oncogenic microRNA, establishing transcript-level suppression as a route to its downregulation in cancer.

   Evidence Luciferase reporter assay of the SCN4B 3'UTR with miR-424-5p plus loss-of-function and xenograft experiments in colorectal cancer cells

   PMID:31785995

   Open questions at the time

   • Downstream effectors linking SCN4B loss to proliferation not mapped
   • Whether RhoA axis mediates the colorectal phenotype not tested
5. 2020 Medium

   Generalized microRNA-mediated SCN4B silencing to prostate cancer and linked SCN4B restoration to EMT marker reversal.

   Evidence Luciferase reporter assay with miR-3175, RT-qPCR, Western blotting of EMT markers and proliferation/migration/invasion assays in prostate cancer cells

   PMID:32833340

   Open questions at the time

   • Direct mechanism by which SCN4B controls EMT markers not defined
   • Single-lab, single-context validation
6. 2026 Medium

   Demonstrated a neuronal role for Scn4b in maintaining striatal spiny projection neuron excitability and modulating Huntington's disease phenotypes in vivo.

   Evidence Scn4b knockout and HD-model overexpression mice analyzed by snRNA-seq, SPN electrophysiology, and behavioral motor/cognitive testing (preprint)

   PMID:41959367

   Open questions at the time

   • Preprint, not yet peer-reviewed
   • Molecular mechanism linking Scn4b to SPN excitability changes not resolved
   • Whether effect is channel-dependent or via the non-channel pathway unknown
7. 2026 Medium

   Confirmed SCN4B as an EMT and proliferation suppressor in lung adenocarcinoma, reinforcing its tumor-suppressive function across cancer types.

   Evidence SCN4B overexpression in A549 and H1299 cells with EMT marker Western blots, wound-healing, Transwell, viability, and apoptosis assays

   PMID:41685607

   Open questions at the time

   • Whether RhoA/C-terminus axis underlies the LUAD effect not tested
   • Single-lab, in vitro only

• The molecular link between the Navβ4 C-terminus and RhoA regulation, and whether this same pathway underlies its EMT-suppressive and neuronal roles, remains unresolved.
• No direct binding partner connecting β4 C-terminus to RhoA identified
• Unclear whether neuronal phenotypes are channel-dependent
• No structural model of Navβ4–Nav1.5 assembly